Improving outcomes of myxomatous mitral valve disease in dogs

Abstract

Now that treatment has been shown to slow the onset of clinical signs of myxomatous mitral valve disease (MMVD), recommendations are focusing on diagnosing the condition before clinical signs manifest so that dogs can be maintained free of signs for longer. This article summarises the published evidence and outlines optimal management for dogs at each disease stage. It covers pharmacological and other strategies, with a view to maintaining dogs in the early stages of the disease for as long as possible and effectively managing their clinical signs when they develop.